| Cancer nanomedicine: a review of recent success in drug delivery PR Stephanie Tran, Peter-Joseph DeGiovanni, Brandon Piel Clinical and Translational Medicine 6 (44), 2017 | 993 | 2017 |
| Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer S Kitajima, E Ivanova, S Guo, R Yoshida, M Campisi, SK Sundararaman, ... Cancer discovery 9 (1), 34-45, 2019 | 365 | 2019 |
| Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses I Cañadas, R Thummalapalli, JW Kim, S Kitajima, RW Jenkins, ... Nature medicine 24 (8), 1143-1150, 2018 | 272 | 2018 |
| 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade AR Aref, M Campisi, E Ivanova, A Portell, D Larios, BP Piel, N Mathur, ... Lab on a Chip 18 (20), 3129-3143, 2018 | 246 | 2018 |
| Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity NR Mahadevan, EH Knelson, JO Wolff, A Vajdi, M Saigí, M Campisi, ... Cancer discovery 11 (8), 1952-1969, 2021 | 126 | 2021 |
| Nanoparticle design strategies for effective cancer immunotherapy P Velpurisiva, A Gad, B Piel, R Jadia, P Rai Journal of Biomedicine (Sydney, NSW) 2 (2), 64, 2017 | 73 | 2017 |
| Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 2019; 9: 34–45. doi: 10.1158/2159-8290 S Kitajima, E Ivanova, S Guo, R Yoshida, M Campisi, SK Sundararaman, ... CD-18-0689.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 64 | |
| Targeting cancer using polymeric nanoparticle mediated combination chemotherapy A Gad, J Kydd, B Piel, P Rai International journal of nanomedicine and nanosurgery 2 (3), 2016 | 60 | 2016 |
| Tumor-derived cGAMP regulates activation of the vasculature M Campisi, SK Sundararaman, SE Shelton, EH Knelson, NR Mahadevan, ... Frontiers in Immunology 11, 2090, 2020 | 53 | 2020 |
| Phosphorylation of Rab7 by TBK1/IKKϵ regulates innate immune signaling in triple-negative breast cancer JL Ritter, Z Zhu, TC Thai, NR Mahadevan, P Mertins, EH Knelson, BP Piel, ... Cancer research 80 (1), 44-56, 2020 | 49 | 2020 |
| MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer S Kitajima, T Tani, BF Springer, M Campisi, T Osaki, K Haratani, M Chen, ... Cancer Cell 40 (10), 1128-1144. e8, 2022 | 45 | 2022 |
| Activation of tumor-cell STING primes NK-cell therapy EH Knelson, EV Ivanova, M Tarannum, M Campisi, PH Lizotte, MA Booker, ... Cancer immunology research 10 (8), 947-961, 2022 | 38 | 2022 |
| Engineering remotely triggered liposomes to target triple negative breast cancer A Sneider, R Jadia, B Piel, D VanDyke, C Tsiros, P Rai Oncomedicine 2, 1, 2017 | 35 | 2017 |
| Liposomes aid curcumin's combat with cancer in a breast tumor model R Jadia, J Kydd, B Piel, P Rai Oncomedicine 3, 94-109, 2018 | 15 | 2018 |
| Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017; 6: 44 S Tran, PJ DeGiovanni, B Piel, P Rai | 15 | |
| Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017; 6 (1): 44 S Tran, PJ DeGiovanni, B Piel, P Rai | 15 | |
| GSK461364A, a polo-like kinase-1 inhibitor encapsulated in polymeric nanoparticles for the treatment of glioblastoma multiforme (GBM) P Velpurisiva, BP Piel, J Lepine, P Rai Bioengineering 5 (4), 83, 2018 | 10 | 2018 |
| Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, B Piel, L Zerefa, N Murugan, CD Coherd, AG Miklosi, ... Molecular Cancer 23 (1), 56, 2024 | 7 | 2024 |
| development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Y Wang, A Buck, M Grimaud, S Kodangattil, C Razimbaud, A Fayed, ... Cancer Research 81 (13_Supplement), 62-62, 2021 | 3 | 2021 |
| fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects Y Wang, A Buck, G Kastrunes, R Abbas, M Lynch, Z Zhong, SM Hoang, ... Cancer Research 83 (7_Supplement), 886-886, 2023 | 1 | 2023 |
Prakash RaiVerified email at uml.edu
